Latanoprost / Timolol Fdc International (Timolol Maleate, Latanoprost)

• Latanoprost/Timolol is indicated for conditions that require reduction of intra‑ocular pressure within the glaucoma disease family.
• Open‑angle glaucoma: lowers eye pressure to slow optic nerve damage.
• Ocular hypertension: reduces pressure to prevent progression to glaucoma.
• Secondary open‑angle glaucoma: helps control pressure when caused by other ocular conditions.

• Timolol maleate non‑selectively blocks β‑adrenergic receptors in the ciliary body, decreasing aqueous humor production. Latanoprost, a prostaglandin F2α analog, binds FP receptors in the eye, enhancing uveoscleral outflow of aqueous humor. The combined actions result in a net reduction of intra‑ocular pressure.

Common Side Effects

• Eye irritation or burning sensation
• Blurred vision shortly after instillation
• Conjunctival hyperemia (redness)
• Foreign body sensation
• Increased eyelash length or thickness
• Darkening of the iris or peri‑ocular skin

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema)
• Paradoxical increase in intra‑ocular pressure
• Corneal edema or keratitis
• Anterior uveitis or iritis
• Systemic beta‑blocker effects such as bradycardia or bronchospasm
• Persistent eye pain or vision loss

• Before using Latanoprost/Timolol, consider the following precautions.
• Cardiovascular assessment: evaluate for bradycardia or heart block.
• Respiratory status: avoid in patients with severe asthma or COPD.
• Sulfonamide allergy: timolol contains a sulfonamide moiety; assess hypersensitivity.
• Ocular pigmentation: monitor for iris or peri‑ocular skin darkening.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost/Timolol may interact with other medicines; review the following.

Major Interactions (Avoid)

• Concurrent systemic beta‑blockers: risk of additive bradycardia.
• Other ocular hypotensive agents: may cause excessive pressure lowering.
• Sympathomimetic eye drops: can reduce timolol efficacy.
• Sulfonamide antibiotics: increased risk of hypersensitivity reactions.
• Multiple prostaglandin analogs: heightened ocular inflammation.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine): may raise timolol plasma levels.
• Anticholinergic eye drops: possible reduction in pressure‑lowering effect.
• Topical NSAIDs: may increase ocular irritation.
• Systemic antihistamines: can exacerbate dry eye symptoms.
• Other beta‑blocker eye drops: monitor for cumulative cardiovascular effects.